[BNews]

Featured STOCK

  • Novo Nordisk’s Obesity Setback: What Kagrama’s Miss vs. Zepbound Means for Investors

    A surprising obesity trial result has shaken confidence in Novo Nordisk (NVO +1.38%) and sharpened the spotlight on Eli Lilly (LLY 2.03%) in this fiercely competitive GLP‑1 race. Watch the video below to see what it could mean for investors. *This video was published on Feb.24, 2026. Andy Cross has no position in any of...

  • Novo Nordisk’s Obesity Setback: What Kagrama’s Miss vs. Zepbound Means for Investors

     

  • Bitcoin rebound appears a ‘relief rally,’ not the start of a new bullish cycle, says CryptoQuant

    "Bitcoin is still inside a bear market, despite the recent price rally," Julio Moreno, head of research at CryptoQuant, said.